69
Participants
Start Date
October 12, 2022
Primary Completion Date
March 11, 2024
Study Completion Date
July 8, 2024
Placebo
0.9% Sterile Normal Saline, USP
Shigella sonnei strain 53G
1.5 x 10\^3 Colony Forming Units (cfu) Shigella sonnei 53G, a virulent strain of wildtype Shigella sonnei
WRSs2
10\^6 Colony Forming Units (cfu) dose of an oral live-attenuated Shigella sonnei vaccine candidate derived from a virulent S. sonnei strain Moseley (WRSs2)-a live, attenuated vaccine that has been manufactured under cGMP conditions at the WRAIR PBF
The Hope Clinic of Emory University, Decatur
Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati
National Institute of Allergy and Infectious Diseases (NIAID)
NIH